Table 2 Pareto classification of health change classification of changes from baseline in EQ-5D dimensions
|  | Enzalutamide (n = 872), n (%) | Placebo (n = 845), n (%) | P value |
|---|---|---|---|
Week 13 | n = 783 (89.8%) | n = 605 (71.6%) |  |
Worsening | 208 (26.6%) | 230 (38.0%) | <0.0001 |
No change | 337 (43.0%) | 242 (40.0%) | Â |
Improvement | 190 (24.3%) | 94 (15.5%) | <0.0001 |
Mixed change | 48 (6.1%) | 39 (6.5%) | Â |
Week 25 | n = 726 (83.3%) | n = 356 (42.1%) |  |
Worsening | 194 (26.7%) | 123 (34.6%) | 0.0078 |
No change | 288 (39.7%) | 151 (42.4%) | Â |
Improvement | 193 (26.6%) | 64 (18.0%) | 0.0018 |
Mixed change | 51 (7.0%) | 18 (5.1%) | Â |
Week 37 | n = 649 (74.4%) | n = 258 (30.5%) |  |
Worsening | 198 (30.5%) | 95 (36.8%) | 0.0666 |
No change | 252 (38.8%) | 100 (38.8%) | Â |
Improvement | 146 (22.5%) | 43 (16.7%) | 0.0512 |
Mixed change | 53 (8.2%) | 20 (7.8%) | Â |
Week 49 | n = 594 (68.1%) | n = 168 (19.9%) |  |
Worsening | 210 (35.4%) | 61 (36.3%) | 0.8192 |
No change | 214 (36.0%) | 74 (44.1%) | Â |
Improvement | 132 (22.2%) | 22 (13.1%) | 0.0093 |
Mixed change | 38 (6.4%) | 11 (6.6%) | Â |
Week 61 | n = 507 (58.1%) | n = 113 (13.4%) |  |
Worsening | 193 (38.1%) | 51 (45.1%) | 0.1644 |
No change | 180 (35.5%) | 41 (36.3%) | Â |
Improvement | 101 (19.9%) | 18 (15.9%) | 0.3299 |
Mixed change | 33 (6.5%) | 3 (2.7%) | Â |